August 14, 2024 by Johns Hopkins University Researchers report potential new treatment regimens for multidrug-resistant TB meningitis18F-Pretomanid exposure in brain and lung tissues of a patient with active tuberculosis. Credit: Sanjay Jain LabIn a preliminary study with a small number of humans, rabbits and mice, researchers at Johns Hopkins Children’s Center say they have developed...
Category: <span>Pharmaceutical Updates</span>
Dupilumab maintains its effectiveness up to five years in patients with eczema: Study
August 12, 2024 by Elana Gotkine Dupilumab maintains its effectiveness up to five years in patients with eczemaFor patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA Dermatology. Celeste M. Boesjes, M.D., from...
Acid Blockers Appear Superior to PPIs in Erosive Esophagitis
Edited by Satish Kumar M August 08, 2024 TOPLINE:While most potassium-competitive acid blockers demonstrate superior healing rates than proton pump inhibitors (PPIs) in patients with erosive esophagitis, both types of treatment offer relief compared with placebo, a meta-analysis suggests. METHODOLOGY:Researchers conducted a database search up to May 31, 2023, for randomized controlled trials of potassium-competitive...
Drug shows promise for treating brain tumors resulting from breast cancer, trial reports
August 8, 2024 by Steven Lee, University of Texas Health Science Center at San Antonio Sacituzumab govitecan (SG) inhibits tumor growth in a xenograft model of intracranial breast cancer. Representative bioluminescent images of control and sacituzumab govitecan treated (25 mg/kg/twice weekly) mice at the start of treatment (top panels) and 2 weeks after treatment (bottom panels)....
New study shows a single experimental shot reduces HIV levels 1,000-fold
August 8, 2024 by Franny White, Oregon Health & Science University A study in nonhuman primates found a dramatic decrease in levels of the monkey form of HIV after one shot of Therapeutic Interfering Particles, or TIPs. The study’s results suggest that one TIP shot could prevent a person living with HIV from passing the...
Dissolvable microneedle patch enables local delivery of immunomodulatory microparticles containing bifunctional molecules for periodontal tissue regeneration
News Release 8-Aug-2024 Peer-Reviewed PublicationShanghai Jiao Tong University Journal Center image: Dual actions of a single compound with both antibiotic and immunomodulatory effects can suppress inflammation and promote tissue regeneration. Fast-dissolving microneedle patch enables minimally invasive and local delivery of biodegradable microparticles as distributive depots for sustained release of therapeutics in diseased tissues. Credit: All...
Research illuminates benefits of taurine: Q&A with professor of pathology
August 8, 2024 by Nicholas Weiler, Stanford University Molecular docking of mouse PTER and N-acetyltaurine. Individual amino acid residues, two zinc ions (dark blue) and one water molecule (light blue) are highlighted. Credit: Nature (2024). DOI: 10.1038/s41586-024-07801-6The amino acid taurine, a common ingredient in energy drinks, is one of the most abundant amino acids in...
Researchers report potent antibiotic that overcomes resistance
August 8, 2024 by Samuel Hanegreefs, Leiden University Unsplash/CC0 Public Domain Science Translational Medicine has published a study by researchers from the Institute of Biology Leiden (IBL) on a potent new antibiotic that can overcome resistance. “The idea was to tweak the original antibiotic and create a next-generation drug,” says Nathaniel Martin, professor of Biological...
Most blood thinner dosing problems happen after initial prescription
July 31, 2024 by University of Michigan Credit: Pixabay/CC0 Public DomainMillions of Americans take anticoagulants, commonly known as blood thinners. These medications work to prevent blood clots that cause heart attack and stroke. More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. DOACs, such as rivaroxaban (brand...
Paxlovid, Vitamin Supplements Show Promise With Long COVID
Medscape Medical News David Brzostowicki July 29, 2024 Paxlovid, an antiviral approved last year to treat acute infections of COVID-19, is showing great potential as a new treatment for long COVID and may be the most promising experimental therapy now being studied for treating the condition. New research offers strong evidence that Paxlovid provides significant...